C11orf65、SLC47A1基因多态性与二甲双胍临床疗效的相关性分析

打开文本图片集

【摘要】 目的：分析中國东南地区汉族2型糖尿病患者中，C11orf65、SLC47A1基因多态性与二甲双胍临床疗效的相关性。方法：对入组的110例初诊为2型糖尿病（T2DM）患者进行为期90 d的二甲双胍单药治疗，二甲双胍剂量根据患者血糖控制情况进行调整，初始剂量为500 mg/d，极量2 550 mg/d，每隔15天调整1次，完成全程治疗的有97例。采用荧光原位杂交法（FISH）对入组患者的血样进行C11orf65、SLC47A1基因型检测。观察二甲双胍给药前后患者的糖尿病各项疗效指标（FPG、HbA1c、HOMA-IR）的变化情况，比较C11orf65和SLC47A1不同基因型患者之间上述疗效指标变化情况是否存在差异。结果：二甲双胍单药治疗90 d后，SLC47A1各基因型之间FPG、HbA1c、HOMA-IR的变化无明显差异（P>0.05）;C11orf65 CC基因型患者的FPG降低值明显高于AA基因型患者（P<0.001），CC基因型患者的FPG降低值明显高于AC基因型患者（P=0.002）;CC基因型患者的HbA1c降低值明显高于AC、AA基因型患者（P<0.05）;CC基因型患者的HOMA-IR降低值明显高于AA、AC基因型患者（P=0.002，P=0.004）。结论：SLC47A1基因多态性对FPG、HbA1c、HOMA-IR的影响无明显差异，C11orf65 携带C等位基因比未携带者对空腹血糖的作用更好，CC基因型比AC基因型对HbA1c的作用更好，C11orf65携带C等位基因比未携带者的HOMA-IR降低得更多。

【关键词】 C11orf65 SLC47A1 二甲双胍 2型糖尿病 单核苷酸多态性（SNP）

[Abstract] Objective： To analyze the correlation between the gene polymorphism of C11orf65 and SLC47A1 and the clinical efficacy of Metformin in patients with type 2 diabetes mellitus of Han nationality in southeast China.Method： The 110 newly diagnosed patients with type 2 diabetes were treated with Metformin monotherapy for 90 days. The dose of Metformin was adjusted according to the patients’ blood glucose control. The initial dose was 500 mg/d and the maximum dose was 2 500 mg/d. A total of 97 patients completed the whole course of treatment. Fluorescence in situ hybridization （FISH） was used to sequence the polymorphisms of SLC47A1 and C11orf65 gene loci in the eolled patients.The changes of various indicators of diabetes before and after Metformin administration between different genotypes of C11orf65 and SLC47A1 were compared. Result： There was no significant difference in FPG， HbA1c， HOMA-IR between SLC47A1 genotypes （P>0.05）.After 90 days of Metformin treatment， FPG decreased significantly in patients with CC genotype C11orf65 compared with patients with AA genotype （P<0.001）， and FPG decreased significantly in patients with CC genotype compared with patients with AC genotype （P=0.002）.The decrease of HbA1c in CC genotype patients was significantly higher than that in AC and AA genotype patients （P<0.05）. The decrease value of HOMA-IR in patients with CC genotype was significantly higher than that in patients with AA and AC genotype （P=0.002， P=0.004）. Conclusion： The effect of SLC47A1 gene polymorphism on FPG， HbA1c， HOMA-IR after 90 days of Metformin treatment is not different. C11orf65 with C allele has a better effect on fasting blood glucose than that without C allele. The effect of CC genotype on HbA1c is better than that of AC genotype.C11orf65 with C allele has a better effect on the reduction of HOMA-IR than that without carrier.

推荐访问： 多态性 相关性 疗效 基因 临床

---